Xarelto indication stays as-is

Share this article:

Too little information—or, specifically, missing information, according to Bloomberg—prompted the FDA to reject Johnson & Johnson's request to expand the indication for the company's blood thinner Xarelto.

The drugmaker wanted the drug to be used to reduce blood clots in coronary artery disease patients. Friday's rejection marked a third miss for this indication.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.